Table 4.
Suggestion for the use of G-CSFs in individual cases. Primary prevention dosage of G-CSFs
| Q16. TC for breast cancera | Q17. CDDP + S-1 for gastric cancerb | Q18. FOLFOXIRI for colorectal cancerc | |
|---|---|---|---|
| n = 145 | n = 187 | n = 183 | |
| I recommend of primary prophylactic administration of G-CSFs | 43 (29.7)d | 1 (0.5) | 23 (12.6) |
| After Grade 4 neutropenia developed, I recommend G-CSFs | 48 (33.1) | 63 (33.7) | 70 (38.2) |
| After FN developed, I recommend G-CSFs | 54 (37.2) | 66 (35.3) | 56 (30.6) |
| I do not recommend G-CSFs | 0 (0.0) | 57 (30.5) | 34 (18.6) |
TC Docetaxel and Cyclophosphamide, CDDP Cisplatin, S-1 Tegafur, gimeracil, and oteracil, FOLFOXIRI Irinotecan, oxaliplatin, and 5-fluorouracil, G-CSF Granulocyte-Colony Stimulating Factor, FN Febrile Neutropenia
aA 67-year-old woman. You plan to treat with TC therapy (docetaxel 75 mg / m2 and cyclophosphamide 600 mg / m2, administered every 3 weeks) as postoperative chemotherapy for breast cancer. What kind of suggestion do you do as a pharmacist?
bA 70-year-old man. As first-line chemotherapy for unresectable gastric cancer, you plan to treat with S-1 and cisplatin combination therapy. What kind of suggestion do you do as a pharmacist?
cA 70-year-old woman. You plan to treat with irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) therapy as first-line chemotherapy for unresectable colon cancer. What kind of suggestion do you do as a pharmacist?
dNumber (percent)